

Probing the drivers of *Staphylococcus aureus* biofilm protein amyloidogenesis and disrupting biofilms with engineered protein disaggregases

Matthew K. Howard,¹ Karlie R. Miller,¹ Brian S. Sohn,¹ Jeremy J. Ryan,¹ Andy Xu,¹ Meredith E. Jackrel¹

AUTHOR AFFILIATION See affiliation list on p. 16.

ABSTRACT Phenol-soluble modulins (PSMs) are the primary proteinaceous component of *Staphylococcus aureus* biofilms. Residence in the protective environment of biofilms allows bacteria to rapidly evolve and acquire antimicrobial resistance, which can lead to persistent infections such as those caused by methicillin-resistant *S. aureus* (MRSA). In their soluble form, PSMs hinder the immune response of the host and can increase the virulence potential of MRSA. PSMs also self-assemble into insoluble functional amyloids that contribute to the structural scaffold of biofilms. The specific roles of PSM peptides in biofilms remain poorly understood. Here, we report the development of a genetically tractable yeast model system for studying the properties of PSMA peptides. Expression of PSMA peptides in yeast drives the formation of toxic insoluble aggregates that adopt vesicle-like structures. Using this system, we probed the molecular drivers of PSMA aggregation to delineate key similarities and differences among the PSMs and identified a crucial residue that drives PSM features. Biofilms are a major public health threat; thus, biofilm disruption is a key goal. To solubilize aggregates comprised of a diverse range of amyloid and amyloid-like species, we have developed engineered variants of Hsp104, a hexameric AAA+ protein disaggregase from yeast. Here, we demonstrate that potentiated Hsp104 variants counter the toxicity and aggregation of PSMA peptides. Further, we demonstrate that a potentiated Hsp104 variant can drive the disassembly of preformed *S. aureus* biofilms. We suggest that this new yeast model can be a powerful platform for screening for agents that disrupt PSM aggregation and that Hsp104 disaggregases could be a promising tool for the safe enzymatic disruption of biofilms.

IMPORTANCE Biofilms are complex mixtures secreted by bacteria that form a material in which the bacteria can become embedded. This process transforms the properties of the bacteria, and they become more resistant to removal, which can give rise to multidrug-resistant strains, such as methicillin-resistant *Staphylococcus aureus* (MRSA). Here, we study phenol-soluble modulins (PSMs), which are amyloidogenic proteins secreted by *S. aureus*, that become incorporated into biofilms. Biofilms are challenging to study, so we have developed a new genetically tractable yeast model to study the PSMs. We used our system to learn about several key features of the PSMs. We also demonstrate that variants of an amyloid disaggregase, Hsp104, can disrupt the PSMs and, more importantly, dissolve preformed *S. aureus* biofilms. We propose that our system can be a powerful screening tool and that Hsp104 disaggregases may be a new avenue to explore for biofilm disruption agents.

KEYWORDS biofilm, phenol-soluble modulins, MRSA, disaggregase, amyloid

Bacteria produce heterogeneous mixtures of proteins, carbohydrates, and DNA that form biofilm matrices in which the bacteria can then become embedded (1).

Editor Matthew Parsek, University of Washington, Seattle, Washington, USA

Address correspondence to Meredith E. Jackrel, mjackrel@wustl.edu.

The authors declare no conflict of interest.

See the funding table on p. 17.

Received 14 March 2023

Accepted 5 April 2023

Published 17 May 2023

Copyright © 2023 Howard et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Upon taking up residence in these matrices, the properties of bacteria are transformed from those of a free-living planktonic state to a multicellular, community-based state (2, 3). This communal living markedly improves the ability of bacteria to develop tolerance to antimicrobial agents and other stressors (1, 4). Biofilms are also highly adherent to surfaces, further promoting the physical resilience of the resident communities (1, 4). For instance, to treat catheter-related infections, antibiotics are often used instead of removing the catheter, which can leave biofilms in place (4). While some microbes are killed, a proportion of the microbes deep within the biofilm can survive. These microbes can then acquire resistance and rapidly recolonize the residual biofilm material (4). Eventually, this can give rise to persistent infections and multidrug-resistant strains, such as methicillin-resistant *Staphylococcus aureus* (MRSA) (1, 3–6). This suggests that therapeutic approaches relying only on killing microbes may be ineffective and highlights the importance of developing new strategies for eradicating biofilms alongside the development of new antimicrobial agents (4). More broadly, biofilms associated with other microbes are responsible for corrosion, biofouling, and contamination of process water, and decreased quality of drinking water (1, 4). Therefore, improved molecular understanding of biofilms and new strategies for removal of biofilms are key goals.

Proteins play a major role in the structure and function of biofilms, which are formed by a range of microbes (1, 4, 7, 8). Phenol-soluble modulins (PSMs) are the primary proteinaceous component of *S. aureus* biofilms and they contribute heavily to biofilm structure (5). They are also virulent peptides that stimulate inflammatory responses and lyse human cells (8, 9). High expression levels of PSMs are directly correlated with the virulence potential of MRSA (5). Further, *S. aureus psm* deletion mutants display impaired formation of biofilms, while induced expression of *psms* restored characteristic biofilm properties (7).

In *S. aureus*, PSM peptides are encoded at three different locations in the genome. There are four PSM α peptides encoded in the *psma* operon, two PSM β peptides encoded in the *psm β* operon, and δ -toxin (3, 6). In solution, each of the PSMs forms amphipathic α -helices that have surfactant properties, which are thought to be responsible for the cytolytic activity of PSMs (3, 10). This amphipathic character also likely contributes to the tendency of PSMs to aggregate and spread on surfaces (3). In their soluble α -helical form, PSMs can hinder the host immune response by recruiting, activating, and lysing human neutrophils (8). PSMs transition from these soluble α -helices to adopt the β -sheet rich amyloid fold for incorporation into the biofilm matrix (8). Amyloid is highly stable and resistant to conditions such as proteases, denaturants, and boiling temperatures, any of which would denature most proteins (11, 12). Due to the high stability of amyloid and the specific features of the PSMs, it is likely that PSMs contribute heavily to biofilm structure, growth, and resilience, and that disruption of PSMs may destabilize biofilms.

Functional amyloids also play an important role in yeast, as yeast have harnessed prions (infectious amyloids) for adaptive purposes and as protein-based genetic elements (13–16). These processes require tight regulation of amyloid formation and deconstruction, which are mediated by the AAA+ ATPase Hsp104 (17). Bacteria also harbor disaggregases from the Hsp100 family; however, these disaggregases, such as ClpB from *E. coli*, are weaker and can only dissolve disordered aggregated proteins but not more stable amyloid proteins (18). Importantly, while globular proteins have highly variable structures, the amyloid fold is relatively conserved (11). Therefore, disaggregases that can dissolve amyloid comprised of one protein may be active against amyloid comprised of other proteins. Indeed, we have demonstrated that yeast Hsp104 can dissolve amyloid and pre-amyloid conformers comprised of many different proteins that are not naturally present in yeast (18). However, this activity was weak and required very high concentrations of Hsp104 (18). We have therefore pioneered approaches to engineer Hsp104 variants with enhanced activity and demonstrated that engineered Hsp104 variants can counter the misfolding of substrates implicated in amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and sarcoma (19–26). Due

to the conserved nature of the amyloid fold, we hypothesized that these same Hsp104 variants may be capable of also dissolving biofilm-associated amyloids. Dissolution of the amyloid component of biofilms could destabilize these matrices and allow for their removal.

The inherent heterogeneity of biofilms makes them very challenging to study in a tractable way, which has also limited the development of modulators of biofilm formation. We therefore sought to employ yeast to develop a simple model system to overcome these hurdles. Here, we describe a new yeast model for studying the toxicity and aggregation of PSMA peptides. We anticipate that this system has several key features that will enable improved screening for modulators of biofilm formation. We used this system to explore the effects of expression of each of the four PSMA peptides and delineate sequence-specific drivers of PSMA host toxicity and aggregation. We demonstrate that potentiated Hsp104 variants, which can dissolve amyloid comprised of different proteins that aggregate in human disease, can also suppress PSMA toxicity and dissolve PSMA aggregates. Further, we show that a potentiated Hsp104 variant, Hsp104^{A503S}, can disassemble preformed *S. aureus* biofilms, suggesting that amyloid disaggregases may be a promising new avenue for the development of biofilm dispersal agents and validating the use of our yeast model system to identify other modulators. We propose that this yeast model system could be a useful platform for further studies of biofilm-associated proteins and suggest that engineered amyloid disaggregases may be a useful tool for the enzymatic disruption of biofilms.

MATERIALS AND METHODS

Yeast strains, media, and plasmids

All yeast were WT BY4741, BY4741 Δ hsp104, or WT W303a Δ hsp104 (*MATa*, *can1-100*, *his3-11,15*, *leu2-3,112*, *trp1-1*, *ura3-1*, and *ade2-1*) (27). Yeast were grown in rich medium (YPD) or in synthetic media lacking the appropriate amino acids. Media was supplemented with 2% glucose, raffinose, or galactose. Plasmids harboring the PSMA genes were generated by synthesizing gBlocks (IDT) with flanking Gateway cloning sites. These fragments were inserted into the indicated vector using Gateway cloning to generate PSMA constructs in pAG423GAL-ccdB, pAG423GAL-ccdB-eGFP, pAG425GAL-ccdB-eGFP, pAG303GAL-ccdB-eGFP, and pAG304GAL-ccdB-eGFP (28). Yeast were then transformed with the indicated plasmids. For integrations, pAG303GAL-ccdB-eGFP constructs were linearized with NheI-HF and pAG304GAL-ccdB-eGFP constructs were linearized with MfeI-HF. pAG416GAL-Hsp104 and variants thereof have been previously described (22, 23). Point mutants of PSMA1-4 were generated using Quikchange site-directed mutagenesis (Agilent) and confirmed by Sanger sequencing.

Yeast transformation and spotting assays

Yeast were transformed according to standard protocols using polyethylene glycol and lithium acetate (29). Hsp104 variants in the pAG416GAL-Hsp104 plasmid were transformed into the indicated strains. For spotting assays, yeast were grown to saturation overnight in raffinose supplemented dropout media at 30°C. Cultures were normalized to an $A_{600\text{nm}} = 1.5$, serially diluted, and spotted in duplicate onto synthetic dropout media containing glucose or galactose. Plates were analyzed after growth for 2–3 days at 30°C. Each experiment was repeated with at least three independent transformations.

Yeast growth curve assays

Yeast cells were grown overnight in raffinose supplemented dropout media at 30°C, harvested, washed, and resuspended in galactose supplemented dropout media to a final density of $OD_{600\text{nm}} = 0.8$. 5 μ L of the cell suspension was added to 195 μ L of galactose supplemented dropout media. All samples were prepared in biological triplicates with independent transformations as well as technical triplicates in 96-well

polystyrene microplates that were covered with breathe-easy sealing strips. Plates were incubated at 30°C with shaking (283 cpm) on a microplate scanning spectrophotometer (Biotek Epoch2). Cell density was monitored every 10 min at 600 nm.

Immunoblotting

Yeast were grown and induced in galactose containing medium for 5 h. Cultures were normalized to $A_{600\text{nm}} = 0.6$, 8 mL yeast cells were harvested, treated in 0.1M NaOH for 5 min at room temperature, and cell pellets were then resuspended into 1× SDS sample buffer and boiled for 4 min. Lysates were cleared by centrifugation at 14,000 rpm for 2 min and then separated by SDS-PAGE (4–20% gradient, BioRad), and transferred to a PVDF membrane. Membranes were blocked in Odyssey Blocking Buffer (LI-COR). Primary antibody incubations were performed at 4°C overnight. Antibodies used were anti-GFP monoclonal (Roche Applied Science), anti-Hsp104 polyclonal (Enzo Life Sciences), and anti-PGK monoclonal (Invitrogen). Membranes were imaged using a LI-COR Odyssey FC Imaging system.

Filter retention assays

Yeast were grown and induced as for immunoblotting above. Following induction, 5 mL of $OD_{600\text{nm}} = 0.5$ cells were harvested and rinsed in sterile water. Yeast were resuspended in 500 μL spheroplasting solution (1.2M D-sorbitol, 0.5 mM MgCl_2 , 20 mM Tris, 50 mM β -mercaptoethanol, 0.5 mg/mL Zymolyase 100T, pH 7.5) for 1 h at 30°C with light shaking. Spheroplasts were pelleted by centrifugation at 500 RCF for 5 min, and the supernatant was discarded. Samples were then resuspended in 100 μL lysis buffer (100 mM Tris, pH 7.5, 500 mM NaCl, 5 mM MgCl_2 , 10 mM BME, 0.5% Triton, and 1% yeast Protease Inhibitor cocktail). Samples were vortexed at high speed for 1 min and then incubated at room temperature for 10 min. Cells were flash frozen in nitrogen. Lysates were thawed at room temperature, 33 μL sample buffer (2X TAE, 20% glycerol, 10% β -mercaptoethanol, and 0.0025% bromophenol blue) was added, and then incubated for 5 min at room temperature. Cellulose acetate membranes were prepared by washing in PBST and then placed on top of a filter paper in a Minifold I 96-well spot-blot array system; 15 μL of each prepared lysate was applied to the cellulose acetate membrane and then washed three times with 200 μL PBST. Membranes were blocked and imaged as described for immunoblotting. To measure total PSM protein, samples were processed for SDS-PAGE followed by immunoblotting. Bound protein was quantified using ImageStudio Lite software (LICOR). The percent of aggregated protein is the ratio of the signal from protein bound to the cellulose acetate membrane divided by the signal from the band on the immunoblot. In experiments investigating the effect of Hsp104 on this ratio, samples were normalized to the appropriate vector control.

Microscopy

Indicated yeast strains were grown overnight in raffinose dropout media at 30°C. Cells were then collected and resuspended in galactose dropout media at 30°C to induce protein expression for either 5 h or 15 h. Following induction, yeast were stained using either Hoechst dye to visualize nuclei or CellTracker Blue CMAC (7-amino-4-chloromethylcoumarin) to visualize vacuoles and imaged on either a Nikon Eclipse TE-2000-E or Zeiss LSM 880 Airyscan microscope. All imaging was performed live. For confocal imaging, agarose pads were prepared with the appropriate galactose induction media, cells were applied to #1.5 cover glass, and edges were sealed with nail polish. Confocal images were deconvolved using Zen Black software (Zeiss). All images were prepared using ImageJ (NIH). Quantification of circularity, area, and perimeter of each focus or vesicle was performed manually.

Biofilm disruption assays

Hsp104, Hsp104^{A503S}, and Hsp104^{DPLA-DWB} were purified as previously described (22). The activity of all variants was confirmed by luciferase reactivation assay prior to use. Hsc70 and Hdj2 were purchased from Enzo Life Sciences. Proteinase K was from Invitrogen. *S. aureus* SH1000 was a gift from Petra Levin, and the *S. aureus* SH1000 $\Delta\alpha\beta\text{psm}$ strain was from Çağla Tükel (8). *S. aureus* was grown to saturation overnight in LB broth at 37°C; 200 μL of culture was added to each well of a 96 well plate, which was then incubated overnight at room temperature. The following day, the wells were washed with water and then treated with Hsp104 (0.5 μM hexamer) supplemented with ATP (5 mM) and an ATP regeneration system (10 mM creatine phosphate, 0.25 μM creatine kinase) in the presence or absence of Hsc70 (0.167 μM) and Hdj2 (0.167 μM) in buffer (25 mM HEPES-KOH, pH 7.4, 150 mM KAOc, 10 mM MgAOc, and 10 mM DTT). Treatment proceeded for 24 h at 37°C. Following treatment, non-adherent cells were removed by washing the plate with sterile water three times. The wells were then stained with crystal violet (1% w/v) for 10 min, washed with sterile water, and allowed to dry overnight. Wells were photographed, and then the dye was solubilized with 200 μL of 95% ethanol. Absorbance was then quantified at 595 nm using a BioTek Epoch 2 plate reader. All experiments were performed with a minimum of two duplicate wells serving as technical replicates, with a minimum of four independent biological replicates for each condition.

RESULTS

A yeast model system for studying phenol-soluble modulins (PSM) aggregation

To study the toxicity and aggregation of PSM peptides in a genetically tractable format, we expressed them in the yeast *Saccharomyces cerevisiae*, which has proven to be an excellent system for studying amyloid formation as well as how protein misfolding drives complex human diseases (22, 26, 30–37). Yeast models have been developed for studying the misfolding of α -synuclein, A β , IAPP, FUS, and TDP-43, in which expression of these proteins in yeast drives phenotypes that closely recapitulate key features of human disease (31–33, 35, 38, 39). Screens using these models have identified small molecule and genetic modifiers of protein misfolding implicated in PD, ALS, Alzheimer's disease, and diabetes (33, 35, 38, 40–42). We anticipated that many of the factors that confound the study of biofilms could be overcome through the use of a simple yeast model system, where we could study the intrinsic properties of the PSM peptides and rapidly screen PSM variants. Screening of PSM variants has typically employed solid-phase peptide synthesis, which cannot be carried out in high throughput. However, large collections of PSM variant sequences can be cloned and readily screened in yeast, allowing for probing of the sequence-specific drivers of PSM toxicity and aggregation.

With this in mind, we chose to study the PSM α peptides, as PSM α peptides are known to be more virulent to the host than the PSM β peptides, giving us the opportunity to develop a tractable system that could be used for screening for modulators of PSM host toxicity (43). We inserted the PSM α sequences (Fig. 1A) into the pAG423GAL-ccdB-GFP plasmid and generated a series of yeast strains each harboring a single copy of PSM α 1-GFP, PSM α 2-GFP, PSM α 3-GFP, or PSM α 4-GFP. We placed PSM expression under control of a tightly regulated galactose-inducible promoter, allowing for inducible expression and passaging without toxicity (28). The C-terminal GFP tag was used in all constructs to improve expression of the short peptides and to allow for their detection by microscopy and immunoblotting. Yeast were then grown to log phase in raffinose-supplemented media and transferred to galactose-supplemented media to induce PSM expression. All four PSM α peptides displayed greater toxicity than a GFP control as monitored by outgrowth on galactose (Fig. 1B). PSM α 1 was just modestly toxic, PSM α 2 and PSM α 3 were moderately toxic, and PSM α 4 was highly toxic. To confirm that the GFP tag did not perturb the properties of the PSM α peptides, we also constructed the series of plasmids without the GFP tag (Fig. S1). When expressed without the GFP tag, the

PSMa peptides displayed somewhat diminished toxicity, likely because the expression of these very short sequences is weaker. Nonetheless, we observed similar toxicity trends in the presence and absence of the GFP tag, so we can conclude that the tag does not confound our studies. In subsequent experiments, we have used the GFP-tagged constructs to enable detection by microscopy and immunoblotting.

We next aimed to determine if the amyloidogenic PSMs are regulated similarly to endogenous yeast prions. It has been shown that expression of a fragment of the huntingtin protein harboring a polyglutamine expansion is toxic in yeast, but this toxicity is dependent upon the presence of the yeast prion $[RNQ^+]$ and the prion disaggregase Hsp104 (44). We therefore tested the dependence of PSMa toxicity on Hsp104 by comparing toxicity in BYWT and $BY\Delta hsp104$ yeast. While deletion of Hsp104, which eliminates the $[RNQ^+]$ prion, eliminates the toxic phenotype of polyglutamine (44), the PSMa fusions were similarly toxic in the WT and $hsp104$ deletion strains (Fig. 1B). These results suggest that the presence of Hsp104 and its prion propagation activity has no effect on the toxicity of the PSMa peptides. For all remaining experiments, we have restricted our studies to use of the $\Delta hsp104$ background so that we could later assess the effects of Hsp104 variants on the PSM peptides in the absence of the WT protein. To more quantitatively compare toxicity, we grew the yeast in liquid culture and monitored growth by measuring OD₆₀₀ (Fig. 1C). The trends we observe in liquid culture closely follow those we observe on solid media. Using immunoblotting, we confirmed that toxicity was not simply due to variation in PSMa expression levels (Fig. 1D).

Next, we explored the correlation between toxicity of the PSMa constructs and their solubility. To monitor aggregation of the PSMa peptides in yeast, we implemented a filter retention assay (45). Here, yeast are spheroplasted to allow for gentle lysis. Extracts are then passed over a non-binding cellulose acetate membrane. Soluble proteins pass through this membrane, while insoluble materials will bind the membrane. The membrane can then be probed by immunoblotting, and the signal is normalized to the expression level of the same protein. In the filter retention assay we found that, as expected, GFP did not bind the cellulose acetate membrane (Fig. 1E and F). In contrast, there was a statistically significant increase in binding of PSMa1, PSMa3, and PSMa4 to the cellulose acetate membrane. PSMa2 also displayed a consistent increase in binding to the cellulose acetate membrane, although this difference was not statistically significant. The insolubility we observe correlates with studies suggesting that PSMa peptides form insoluble amyloid or amyloid-like structures (46–48). Specifically, it has been shown that while purified PSMa1, PSMa3, and PSMa4 each form insoluble fibrils, under similar conditions, PSMa2 does not fibrillize or form alternative aggregates, although it can undergo seeded assembly to form ThioflavinT reactive species (48). Thus, we conclude that our system can be used to study the toxicity and aggregation of PSMa peptides. Our system recapitulates known features of the peptides, validating our rationale for use of this platform to screen for modulators of PSMa peptide toxicity and aggregation.

PSMa peptides form vesicle-like structures in yeast

To further characterize the aggregation of the PSMa peptides in yeast, we used fluorescence microscopy. Here, we integrated two copies of each PSMa peptide using the pAG303GAL-*ccdB*-GFP and pAG304GAL-*ccdB*-GFP plasmids (28) to ensure similar PSMa expression levels across the entire population of yeast cells of a given strain. We assessed the toxicity of these strains and found that PSMa2, PSMa3, and PSMa4 were all toxic in this format (Fig. S2A). However, toxicity was diminished as compared to the higher copy strains used earlier (Fig. 1), so we did not observe toxicity for the strain expressing PSMa1, though we did detect expression of each of the PSMa proteins, with weaker expression for PSMa1 (Fig. S2B). Upon expression in yeast, we anticipated that if the PSMa peptides aggregated we would observe cytoplasmic foci, while if they did not aggregate we would observe diffuse cytoplasmic fluorescence (Fig. 2). We observed that while GFP alone displayed diffuse fluorescence throughout the cell, appending PSMa1 to




FIG 1 PSM α peptides are toxic and form insoluble inclusions when expressed in yeast. (A) A sequence alignment of PSM α 1-4 was generated using Clustal Omega. (B) BY WT and BY Δ hsp104 yeast were transformed with the indicated 423GAL-PSM α -GFP plasmid or 423GAL-GFP control. Strains were serially diluted fivefold and spotted on glucose (off) or galactose (on) media. (C) BY Δ hsp104 strains from B were grown in liquid culture and growth was monitored by measuring absorbance at 600 nm over 3 days. Solid lines show the average of three replicates, and hashed lines show \pm SEM, $N = 3$. (D) BY Δ hsp104 strains from B were induced for 5 h, lysed, and immunoblotted. Uninduced cells serve as a control. 3-Phosphoglycerate kinase (PGK) serves as a loading control. Hashed line indicates where the blot was spliced for presentation, though all samples were run on the same blot. (E) BY Δ hsp104 strains from B were induced for 5 h, spheroplasted, and lysed. Extracts were then passed over a nonbinding cellulose acetate (CA) membrane. Membranes were then probed using an anti-GFP antibody. Representative results from three biological replicates are shown. (F) The ratio of aggregated protein (bound to CA) to total protein (detected via immunoblotting) was calculated. Aggregation of the PSM α proteins were compared to the GFP control using a one-way ANOVA with Dunnett's multiple comparison test ($N = 3$, individual points shown as dots, bars show mean \pm SEM, **** $P < 0.0001$, and *** $P < 0.001$).

GFP led to the accumulation of cytoplasmic foci in nearly all of the yeast cells following 5 h of induction (Fig. 2A and C). We also observed accumulations in nearly all yeast cells upon expression of PSM α 2, PSM α 3, and PSM α 4 (Fig. 2A and C). Strikingly, rather than the small puncta we observe for PSM α 1, many of these accumulations appeared to be hollow spheres of protein that we have not previously observed.

To study possible clearance mechanisms of these accumulations over time, we imaged the yeast at both 5 and 15 h following induction (Fig. 2B). For PSM α 1, at 15 h following induction we observe few foci, with nearly all of the yeast displaying accumulation of fluorescence in the vacuole (Fig. 2 and Fig. S2C, vacuoles are outlined). The vacuole is a site where misfolded proteins and protein aggregates are typically shuttled for degradation, and transit to the vacuole suggests that PSM α 1 is effectively processed for degradation. This transit to the vacuole and consequential increased degradation likely also explains the decreased expression and toxicity noted for PSM α 1 (Fig. S2B). In contrast, we observe that the cytoplasmic spherical structures persist at this same 15 h




FIG 2 PSMα peptides form foci and vesicle-like structures in yeast. (A) *BYΔhsp104* yeast integrated with two copies of the indicated PSMα peptide or vector control in the 303GAL-PSMα-GFP and 304GAL-PSMα-GFP vectors were analyzed by fluorescence microscopy after 5 h (left) and (B) 15 h (right) of induction. Vacuoles, where apparent, are outlined with a white line. Scale bars = 5 microns. See Fig. S2 for images with a vacuole-specific dye. (C) Quantification of the microscopy images from A and B. *N* = 3, individual points are shown as dots, and bars show mean ± SEM. (D) Superresolution microscopy of the strains after 5 h of induction reveals accumulation of hollow spherical vesicle-like structures. Clusters of vesicles are indicated by white arrowheads. Scale bar = 1 micron. Quantification of puncta and vesicle circularity, area, and perimeter is shown in Fig. S2D to F.

timepoint for strains expressing PSMα2, PSMα3, and PSMα4, although there does seem to be some dispersal of the clusters of spheres. We quantified these effects by counting the number of yeast cells at 5 and 15 h with aggregates and/or vesicles, vacuolar accumulation of GFP, or both (Fig. 2C and Fig. S2C). For PSMα1, following 5 h of induction we find that nearly 100% of cells display aggregates, while following 15 h of induction, nearly 100% of cells display vacuolar PSMα1. Yeast expressing PSMα2 and PSMα4 show

little shift in localization over time. Interestingly, PSMa3 shows a more intermediate effect, where a greater subset of cells displays vacuolar accumulation of PSMa3 after 15 h of expression. Although there is notable transit of PSMa3 to the vacuole, these cells also retained some aggregates in the cytoplasm and in vesicles, which cannot be cleared and remain toxic to the cell. Thus, we propose that accumulations of PSMa1 are the most readily cleared from the cell, and this transit of PSMa1 to the vacuole detoxifies PSMa1. In contrast, aggregates and vesicles comprised of PSMa2, PSMa3, and PSMa4 persist, correlating with their enhanced toxicity.

To more closely examine the spherical structures we observed, which were especially apparent for the strain expressing PSMa4, we studied the strains using superresolution confocal microscopy (Fig. 2D). As found previously (Fig. 2A), we observed abundant puncta throughout the cytoplasm for the PSMa1 strain. However, for PSMa2, PSMa3, and PSMa4, we observed clusters of spherical, hollow, vesicle-like structures, which we now refer to as vesicles (Fig. 2D, vesicles are indicated with arrowheads). To quantify the differences in puncta morphology among the four PSMa strains, we calculated the circularity, area, and perimeter of the puncta (PSMa1) or vesicles (PSMa2, PSMa3, and PSMa4). We find that both the PSMa1 puncta and PSMa2, PSMa3, and PSMa4 vesicles are nearly spherical, though the vesicles are somewhat more circular than the PSMa1 puncta (Fig. S2D). The vesicles of PSMa2, PSMa3, and PSMa4 have both a larger area and perimeter as compared to the PSMa1 puncta (Fig. S2E to F). These vesicle structures likely form due to the surfactant properties of the peptides and may be similar to the cytolytic extracellular vesicles secreted by *S. aureus*, where the formation of these vesicles is dependent on the presence of PSMa peptides (49).

Sequence-specific drivers of PSMa toxicity and aggregation

To define the basis for the differences in toxicity we observed, we next aimed to predict and test how various substitutions would modulate the aggregation and toxicity of the PSMa peptides. To do so, we compared the sequences of PSMa1, PSMa2, and PSMa4 by constructing a sequence alignment using Clustal Omega (Fig. 3A). We excluded PSMa3 from our analysis because it adopts a non-canonical α -helical conformation in the fibrillar form, restricting our ability to make direct comparisons (46). The sequence identity between PSMa1 and PSMa2 is approximately 86%, while the identities between PSMa1 and PSMa4, as well as between PSMa2 and PSMa4, are approximately 45%. Looking for nonconservative mutations, we noted that glycine was present in PSMa1 and PSMa2 at position 6, while threonine is in this position in PSMa4. Aside from this site, conservation at the remaining positions was rather high between the three peptides. We therefore further analyzed the role of glycine and threonine at position 6. We constructed PSMa1^{G6T}, PSMa2^{G6T}, and PSMa4^{T6G}, each in the pAG423GAL-ccdB-GFP plasmid, and assessed toxicity (Fig. 3B). We find that substitution of threonine for glycine in PSMa1 and PSMa2 enhances their toxicity. In contrast, substitution of glycine for threonine in PSMa4 suppresses its toxicity. These results suggest that substitution of glycine for threonine at this position might be a key modulator of the properties of PSMa peptides.

To further explore the effects of these substitutions, we examined these sequences using the program ZipperDB (50). ZipperDB is a structure-based threading algorithm that scores six amino acid segments for propensity to form self-complementary β strands, or steric zippers, which comprise the spine of amyloid fibrils. Rosetta energies are calculated, with a threshold of -23 kcal/mol corresponding to amyloidogenicity. Results from this ZipperDB analysis (Fig. 3C) support the conclusions from our toxicity assays. We observe that for both PSMa1 and PSMa2, the G6T substitution enhances the propensity of this region to form a steric zipper. In contrast, introduction of the T6G substitution in PSMa4 decreases the propensity of this region to form a steric zipper.

To determine if these changes in toxicity correlate with predicted changes in solubility, we again performed filter retention assays (Fig. 3D). The trends that we observe correlate with those from the toxicity assays and the ZipperDB analysis. Relative to their WT counterparts, we observe a mild increase in insolubility for PSMa1^{G6T} and a more




FIG 3 Missense mutations of PSMα residue 6 drive propensity for aggregation, toxicity, and solubility. (A) Sequence alignment PSMα1, PSMα2, and PSMα4 indicates lack of conservation at residue 6. (B) *BYΔhsp104* yeast were transformed with the indicated 423GAL-PSMα-GFP plasmid or 423GAL-GFP control. Strains were serially diluted 5-fold and spotted on glucose (off) or galactose (on) media. (C) Analysis of the sequences by ZipperDB (50). Steric zippers are predicted to form when the Rosetta energy of a hexapeptide is below the threshold of -23 kcal/mol, which is denoted by a hashed line. (D) Strains from B were induced for 5 h, spheroplasted, and lysed. Extracts were then passed over a nonbinding cellulose acetate (CA) membrane. Membranes were then probed using an anti-GFP antibody. Representative results from three replicates are shown (top row). Extracts were also probed via immunoblotting to assess total GFP (second row). The ratio of aggregated protein (top row, bound to CA) to total PSMα-GFP protein (second row, from immunoblotting) was calculated (bottom). Aggregation of each WT PSMα protein was compared to its respective mutant using two-tailed t-tests. ($N \geq 6$, bars show mean \pm SEM, $*P < 0.05$, and $**P < 0.01$). Note that the shown filter retention assay and immunoblotting samples were all run on a single membrane in a randomized order, with a single representative trial shown. Lanes are cropped and re-ordered for presentation purposes.

robust increase in insolubility for PSMa2^{G6T}. We also observe a slight, but not statistically significant, decrease in insolubility for PSMa4^{T6G}. These results suggest that this site may be a key modulator of PSMa aggregation and that our system can be used to probe the molecular drivers of PSMa amyloid formation.

Potentiated Hsp104 variants suppress the toxicity of PSMa peptides

With a new system for studying the mechanisms and modulators of PSMa toxicity and aggregation in hand, we were next interested in using this system to investigate potential modulators of PSMa aggregation. Previous studies have shown that a diverse range of amyloid and amyloid-like proteins can be solubilized by variants of Hsp104, an AAA+ ATPase protein disaggregase from yeast (22, 26, 51–53). While Hsp104 has limited activity against most of these non-native misfolded substrates, we have engineered potentiated variants harboring missense mutations that display robust remodeling activity (18, 22–24, 54). We therefore hypothesized that these same potentiated Hsp104 variants that can remodel substrates, including α -synuclein, TDP-43, and FUS, may also be capable of remodeling PSMa peptides. We coexpressed PSMa2, PSMa3, and PSMa4 with Hsp104 and a series of variants: Hsp104^{V426L}, Hsp104^{A437W}, Hsp104^{A503G}, Hsp104^{A503S}, Hsp104^{A503V}, Hsp104^{Y257F-A503V-Y662F} (Hsp104^{A503V-DPLF}), Hsp104^{Y507V}, and Hsp104^{N539K}, which represent a range of variants that have been identified to suppress the toxicity, misfolding, and mislocalization of α -synuclein, TDP-43, and FUS (22, 23). To assess the effects of Hsp104 expression on PSMa toxicity and aggregation, we modified our PSMa strains. We found that toxicity of the integrated PSMa2 strain decreased substantially upon introduction of a third plasmid (Fig. S3), so we instead employed a strain expressing two copies from pAG423GAL-PSMa2-GFP and pAG425GAL-PSMa2-GFP (Fig. 4) to drive higher expression of PSMa2 as compared to the single copy strain used in Fig. 1. We also used this higher expression format for testing Hsp104 variants against PSMa1 (Fig. S3), which is also only weakly toxic when integrated (Fig. S2A). For PSMa3 and PSMa4, we employed the strains with two integrated copies of each PSMa peptide (Fig. 2 and Fig. S2A).

Hsp104 does not suppress the toxicity of α -synuclein, TDP-43, or FUS in yeast (22), and we similarly find that Hsp104 does not suppress the toxicity of PSMa2, PSMa3, or PSMa4 (Fig. 4A). In contrast, each of the potentiated Hsp104 variants tested robustly suppresses the toxicity of PSMa2. The strain integrated with PSMa3 did not display very high toxicity but we still observe a strong rescue by each of the variants. PSMa4 toxicity was more robust than PSMa3, and we again observe that each of the potentiated variants tested strongly suppresses this toxicity, restoring growth to a level similar to that of yeast expressing no PSMa4. Against PSMa1, we observed no rescue by Hsp104 variants (Fig. S3). To confirm that these changes are not simply due to altered expression levels, we measured expression of the PSMa peptides and each of the Hsp104 variants, and we observe consistent expression levels for each strain (Fig. 4B and Fig. S3). To further assay these changes in toxicity we monitored growth in liquid culture for two of the better characterized variants, Hsp104^{A503S} and Hsp104^{A503V-DPLF}. We observe trends similar to those from the spotting assays. Again, Hsp104 does not suppress PSMa2 toxicity while the two potentiated variants robustly counter this toxicity. Against PSMa3, the two potentiated variants and Hsp104 have similar effects in suppressing toxicity relative to PSMa3 alone. Against PSMa4, we note robust toxicity suppression by both Hsp104^{A503S} and Hsp104^{A503V-DPLF}, while Hsp104 does not modify PSMa4 toxicity (Fig. 4C). Thus we conclude that Hsp104 variants can suppress the toxicity of PSMa proteins, which also validates use of this model for screening for modulators of biofilm protein amyloidogenesis.

Potentiated Hsp104 variants counter PSMa aggregation and vesicle formation

We next aimed to determine if the Hsp104 variants clear PSMa aggregates and vesicles in yeast. To do so, we performed superresolution fluorescence microscopy following 5 h of




FIG 4 Potentiated Hsp104 variants suppress the toxicity of PSM α peptides. (A) BY Δ *hsp104* yeast was transformed with 423/425GAL-PSM α 2-GFP while w303 Δ *hsp104* yeast was transformed with 303/304GAL-PSM α 3-GFP or 303/304GAL-PSM α 4-GFP. The resulting strains were transformed with the indicated 416GAL-Hsp104 variant or vector control. Strains were serially diluted fivefold and spotted on glucose (Glu, off) or galactose (on) media. Only the most dilute spots are shown for the glucose control plates. (B) Strains from A were induced for 5 h, lysed, and immunoblotted. Uninduced cells serve as a control. 3-Phosphoglycerate kinase (PGK) serves as a loading control. (C) Selected strains from A were grown in liquid culture, and growth was monitored by measuring absorbance at 600 nm over 3 days. Solid lines show the average of three biological replicates. Hashed lines show \pm SEM.

induction. For PSM α 2, we observed the accumulation of clusters of vesicle-like structures that are not cleared by Hsp104 (Fig. 5A, vesicles denoted with arrowheads). Upon expression of Hsp104^{A503S}, these vesicles appear larger and less spherical. Upon expression of Hsp104^{A503V-DPLF}, fewer vesicle-like structures were noted. These results correlate with the results of the toxicity assays, where Hsp104^{A503V-DPLF} more robustly suppresses toxicity as compared to Hsp104^{A503S}, suggesting that clearance of these structures alleviates their toxicity. We next monitored the strains expressing PSM α 3 (Fig. 5B). We again find that the accumulations of vesicle-like structures of PSM α 3 are not modified by Hsp104. However, both of the potentiated variants clear these structures. Finally, we performed these experiments with PSM α 4 (Fig. 5C) and again find that vesicle-like structures accumulate and persist upon expression of Hsp104. Upon expression of the two potentiated variants, vesicle-like structures remain. However, they appear to have

altered morphology and are less clustered, suggesting they are being more subtly remodeled.

To determine if these changes are due to solubilization of the accumulations, we again employed filter retention assays. We find that PSMa2 remains primarily soluble in yeast (Fig. 1E and F; Fig. 5D). Nonetheless, Hsp104^{A503S} and Hsp104^{A503V-DPLF} subtly solubilize PSMa2, though these effects are not statistically significant. Against PSMa3, both potentiated variants solubilize approximately 50% of the aggregated material (Fig. 5E). Finally, we find that both Hsp104^{A503S} and Hsp104^{A503V-DPLF} solubilize PSMa4, clearing ~50% and 25% of PSMa4, respectively (Fig. 5F). Thus, we conclude that potentiated Hsp104 variants can eliminate PSMa vesicles and solubilize PSMa protein.

A potentiated Hsp104 variant, Hsp104^{A503S}, can disassemble *S. aureus* biofilms

We next sought to investigate if potentiated Hsp104 variants could drive the disassembly of complex biofilm matrices. To do so, we grew *S. aureus* SH1000 in microtiter plates and then treated these biofilms with purified Hsp104, Hsp104^{A503S}, or Hsp104^{A503S} supplemented with co-chaperones Hsp40 and Hsp70 (Fig. 6A). To validate our approach, we first compared biofilm formation between *S. aureus* SH1000 and SH1000 $\Delta\alpha\beta\text{psm}$, which cannot produce PSMa or PSM β peptides (8). As a positive control for biofilm disruption, we used Proteinase K, which has been shown to disrupt biofilms by non-specific digestion of proteins (8). Following treatment with buffer or Proteinase K for 24 h, we stained the biofilms with crystal violet dye, photographed the residual material, and then resuspended and quantified the signal (Fig. 6A and B). We find that treatment with Proteinase K decreases biofilm biomass produced by SH1000 *S. aureus* by approximately 50%. The $\Delta\alpha\beta\text{psm}$ strain decreased biomass formation by approximately 25%. As expected, treatment of the $\Delta\alpha\beta\text{psm}$ strain with Proteinase K does not further decrease biofilm biomass. Next, we treated the SH1000 biofilms with Hsp104 (Fig. 6C). Treatment with the chaperones Hsp40 and Hsp70 alone subtly decreased biomass, but this effect was not significant. Treatment with Hsp104^{WT} had no effect on biomass while Hsp104^{A503S} had a subtle but non-statistically significant effect on the biofilm. However, treatment with Hsp104^{A503S} disaggregase in combination with its co-chaperones Hsp40 and Hsp70 drives a visible decrease in biomass, corresponding to a 25% reduction in biofilm biomass (Fig. 6C). As a negative control, we also treated SH1000 biofilms with Hsp104^{Y257A-E285Q-Y662A-E687Q} (Hsp104^{DPLA-DWB}), an ATPase dead, substrate-binding deficient mutant (18). This variant also had no effect on biofilm biomass. Finally, to confirm that the changes we observe are specific to disruption of the PSM component, we treated the $\Delta\alpha\beta\text{psm}$ strain with Hsp104 (Fig. 6D). As expected, we see no significant change in biofilm biomass upon treatment of these materials with Hsp104 or the potentiated Hsp104^{A503S} variant complemented with Hsp40 and Hsp70. We therefore conclude that Hsp104^{A503S} can disrupt preformed *S. aureus* biofilm matrices, which validates use of our yeast model system as a useful tool for identifying biofilm modulators and provides further support for the idea that disruption of the proteinaceous component of *S. aureus* biofilms can destabilize them sufficiently to allow for removal.

DISCUSSION

Biofilms are poorly defined heterogeneous mixtures that are challenging to study using conventional approaches (1, 4, 7). Here, we demonstrate that the aggregation of *S. aureus* biofilm-associated proteins can be studied by use of a simple yeast model system. We have established that this system can be used as a platform for studying the toxicity, aggregation, and solubility of PSMa peptides in a genetically tractable manner. We find that PSMa toxicity and solubility in yeast recapitulate known features of these peptides. Expression of the PSM peptides also leads to the accumulation of unusual spherical vesicle-like structures, presumably due to the surfactant character of the peptides. These structures resemble the extracellular vesicles that are secreted by *S. aureus*, which is a process that relies upon the presence of PSMa peptides (49). Using this system, we have identified a key position where substitution of glycine for threonine correlates with key




FIG 5 Potentiated Hsp104 variants disrupt PSMA vesicle structures and solubilize PSMA proteins. (A) $\Delta hsp104$ yeast integrated with 303/304GAL-PSMa2-GFP were transformed with the indicated 416GAL-Hsp104 variant or 416 GAL vector control. Strains were induced for 5 h, stained with Hoechst to visualize nuclei (blue), and imaged. (B) Experiments were performed as in A but with PSMA3. (C) Experiments were performed as in A but with PSMA4. Vesicles are indicated by arrowheads. Scale bar = 3 microns. (D) Strains from A were processed for a filter retention assay following 5 h of induction. CA membranes were probed using an anti-GFP antibody. Representative results from three replicates are shown (top). The ratio of aggregated protein (bound to CA) to total PSMA-GFP protein was calculated. (bottom). (E) Experiments were performed as in D but with PSMA3. (F) Experiments were performed as in D but with PSMA4. For D-F $N = 3$, individual points are shown as dots, and bars show mean \pm SEM. Aggregation of the PSMA proteins when coexpressed with Hsp104 and Hsp104 variants were compared to the GFP control using a one-way ANOVA with Dunnett's multiple comparison test, * $P < 0.1$, *** $P < 0.01$, **** $P < 0.001$.

differences noted in PSMA peptide properties. Finally, we have demonstrated that variants of the AAA+ disaggregase Hsp104 are capable of suppressing the toxicity and aggregation of the PSMA peptides and that they are further able to destabilize pre-formed biofilm matrices to facilitate their removal. It is important to note that Hsp104^{A503S} was originally isolated in a screen against the ALS-associated protein TDP-43, so it has not been substrate-optimized to disrupt the PSMA proteins (55). Thus in the future, it will be important to further boost the disaggregase activity of Hsp104^{A503S} against the PSMA peptides through protein engineering. This tunable activity and dissolution without proteolysis represent key benefits to this strategy. Our work suggests that further efforts to develop and apply potentiated Hsp104 variants may be a useful strategy for disrupting heterogeneous biofilm matrices, including those of diverse bacteria beyond just those of *S. aureus*.

We have employed this newly developed yeast model system to define key differences between PSMA1, PSMA2, and PSMA4, which have relatively similar sequences but distinct properties. We find that a single missense substitution of glycine for threonine at




FIG 6 Hsp104^{A503S} disrupts *S. aureus* biofilm formation. (A) Schematic depicting the experimental design was created using BioRender.com. (B) SH1000 WT or SH1000 $\Delta\alpha\beta ps m$ *S. aureus* was incubated in 96 well plates for 24 h to allow biofilm biomass to accumulate. Following washing, residual biomass was stained with crystal violet dye to visualize biomass. Images (top) show wells that are all from a single trial. Wells were then resuspended and quantified. Biomass for each condition was compared to the treatment of SH1000 *S. aureus* control treated with buffer using a two-tailed, unpaired t-test. ($N \geq 6$ biological replicate trials, with three technical replicate wells for each trial, bars show mean \pm SEM, $**P < 0.01$, $****P < 0.0001$, and $ns P > 0.05$).

(C) Experiments were performed as in B using SH1000 WT *S. aureus*. Here, following washing, residual biomass was treated with buffer, Hsp104^{WT}, Hsp104^{A503S}, or Hsp104^{DPLA-DWB} plus or minus Hsp40 and Hsp70, as indicated, for 24 h at 37°C. Wells were then stained with crystal violet to visualize biomass. Images shown depict wells that are all from a single trial (top). Wells from B were resuspended and quantified (bottom). Biomass for each condition was compared to control treatment with buffer using a two-tailed, unpaired t-test. ($N \geq 4$ biological replicate trials, with two technical replicate wells for each trial, bars show mean \pm SEM, $*P < 0.05$, $****P < 0.0001$, and $ns P > 0.05$).

(D) Experiments were performed as in C using SH1000 $\Delta\alpha\beta ps m$ *S. aureus*. Following treatment, wells were stained with crystal violet to visualize biomass (top) and then resuspended and quantified (bottom). Biomass for each condition was compared to control treatment with buffer using a two-tailed, unpaired t-test. ($N \geq 4$ biological replicate trials, with three technical replicate wells for each trial, bars show mean \pm SEM, and all P values were greater than 0.05).

position 6 enhances the toxicity and insolubility of PSMA1 and PSMA2, while in the PSMA4 sequence, substitution of threonine for glycine has the opposite effect. We hypothesize that these effects are due to threonine increasing the steric zipper content of this region, which is supported by our ZipperDB calculations. These findings support the relevance of using this simple model system as a platform for studying the drivers of host toxicity and aggregation of biofilm-associated proteins. It may be informative to use this system to explore the full sequence space of these peptides to comprehensively map the drivers of PSM aggregation. Such an approach could overcome inherent limitations when studying a small subset of variant peptides using traditional approaches that are reliant on solid-phase peptide synthesis. Furthermore, we anticipate that this yeast model system could be a broadly useful platform for screening for modulators of PSMA protein aggregation that could overcome many of the limitations of current approaches for assaying biofilm disruption.

Disruption of biofilms is a key goal for healthcare, water treatment, and other applications (1–4). Just as the amyloid component of PSMA peptides stabilizes biofilms and makes them resilient, disruption of this component could destabilize biofilm matrices and make their removal more straightforward. Our results indicate that Hsp104^{A503S} disrupts preformed biofilm matrices and facilitates their removal, suggesting that in practice, purified Hsp104 variants could be applied to surfaces to disrupt the amyloid component, allowing for the removal of the biofilm under mild conditions. Based on the results presented in this study, the currently in-hand Hsp104 variants may be sufficiently active for use in this context. However, we do note incomplete clearance of the vesicle structures and only a 25% reduction in biofilm biomass, though this reduction is of a similar magnitude to that achieved by genetic deletion of PSMA and PSM β . In the future, it may be necessary to further engineer Hsp104 for this particular application. Further, because biofilms are comprised of multiple components that collectively promote adherence, including polysaccharides and DNA, it may be important to disrupt additional components of the biofilm to allow for complete removal. Should further engineering of Hsp104 be necessary, we envision incorporating our yeast model into an approach similar to those used for isolating enhanced Hsp104 variants that counter TDP-43, FUS, and α -syn toxicity (22–24, 55). In sum, we have demonstrated that this new yeast model system can be used to study and uncover key features of the amyloid component of biofilms and that Hsp104 disaggregases can be applied as a novel tool for biofilm disruption and removal.

ACKNOWLEDGMENTS

We thank Peter Bayguinov and Dennis Oakley for their assistance with microscopy. We thank Petra Levin, Courtney Reichhardt, Timothy Wenczewicz, and members of the Jackrel Lab for helpful discussions and feedback.

Our studies were supported by NIH grants F31GM140622 (to J.J.R.) and R35GM128772 (to M.E.J.). Confocal imaging experiments were performed in part through the use of Washington University Center for Cellular Imaging (WUCCI). Superresolution data were data generated on a Zeiss LSM 880 Airyscan Confocal Microscope that was purchased with support from the Office of Research Infrastructure Programs (ORIP) under grant OD021629.

The authors declare no competing interests.

AUTHOR AFFILIATION

¹Department of Chemistry, Washington University, St. Louis, Missouri, USA

AUTHOR ORCID*s*

Meredith E. Jackrel  <http://orcid.org/0000-0003-4406-9504>

FUNDING

Funder	Grant(s)	Author(s)
National Institute of General Medical Sciences	R35GM128772	Meredith Jackrel

AUTHOR CONTRIBUTIONS

Matthew K. Howard, Investigation, Methodology, Writing – original draft, Writing – review and editing | Karlie R. Miller, Investigation, Methodology, Writing – review and editing | Brian S. Sohn, Investigation, Writing – review and editing | Jeremy J. Ryan, Resources, Writing – review and editing | Andy Xu, Investigation, Writing – review and editing | Meredith E. Jackrel, Funding acquisition, Investigation, Methodology, Resources, Supervision, Writing – original draft, Writing – review and editing

ADDITIONAL FILES

The following material is available [online](#).

Supplemental Material

FIG S1 (mBio00587-23-s0001.tif). PSMa peptides expressed without a GFP tag are toxic in yeast. *BYΔhsp104* yeast were transformed with the indicated 423GAL-PSMa plasmid or 423GAL empty vector control. Strains were serially diluted fivefold and spotted on glucose (off) or galactose (on) media. Toxicity trends without the GFP tag were similar to the trends with the plasmids with a C-terminal GFP tag.

FIG S2 (mBio00587-23-s0002.tif). Further characterization of strains from Figure 2. (A) *w303Δhsp104* strains were integrated with two copies of the indicated PSMa peptide or vector control using the 303GAL-PSMa-GFP and 304GAL-PSMa-GFP vectors. Strains were serially diluted fivefold and spotted on glucose (off) or galactose (on) media. (B) Strains from A were induced for 5 h, lysed, and immunoblotted. 3-Phosphoglycerate kinase (PGK) serves as a loading control. (C) Strains from A were induced for 15 h and stained with CellTracker Blue CMAC (7-amino-4-chloromethylcoumarin) to visualize the vacuoles. Scale bar = 5 microns. (D-F) Puncta (PSMa1) or vesicle (PSMa2-4) circularity, area, and perimeter were calculated from images as acquired in Fig 2D following 5 h induction. Values were compared to each other using a one-way ANOVA with Tukey's multiple comparisons test ($N \geq 100$, individual points shown as dots, bars show means, * $p < 0.05$ and **** $p < 0.0001$).

FIG S3 (mBio00587-23-s0003.tif). Potentiated Hsp104 variants do not suppress the toxicity of PSMa1 and subtly suppress PSMa2 toxicity when PSMa2 is expressed at low levels. (A) *w303Δhsp104* yeast was transformed with 423GAL-PSMa1-GFP and 425GAL-PSMa1-GFP and then subsequently transformed with the indicated 416GAL-Hsp104 variant or vector control. Strains were serially diluted fivefold and spotted on glucose (off) or galactose (on) media. (B) Strains from A were induced for 5 h, lysed, and immunoblotted. Uninduced cells serve as a loading control. 3-Phosphoglycerate kinase (PGK) serves as a loading control. (C) *w303Δhsp104* yeast was transformed with 303GAL-PSMa2-GFP and 304GAL-PSMa2-GFP and then subsequently transformed with the indicated 416GAL-Hsp104 variant or vector control. Spotting assays were performed as in A. (D) Strains from C were processed for immunoblotting as in B. Results with 423GAL-PSMa2-GFP and 424GAL-PSMa2-GFP are shown in Figure 4.

REFERENCES

- Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. 2016. Biofilms: an emergent form of bacterial life. *Nat Rev Microbiol* 14:563–575. <https://doi.org/10.1038/nrmicro.2016.94>
- Rumbaugh KP, Sauer K. 2020. Biofilm dispersion. *Nat Rev Microbiol* 18:571–586. <https://doi.org/10.1038/s41579-020-0385-0>
- Peschel A, Otto M. 2013. Phenol-soluble modulins and staphylococcal infection. *Nat Rev Microbiol* 11:667–673. <https://doi.org/10.1038/nrmicro3110>
- Koo H, Allan RN, Howlin RP, Stoodley P, Hall-Stoodley L. 2017. Targeting microbial biofilms: current and prospective therapeutic strategies. *Nat Rev Microbiol* 15:740–755. <https://doi.org/10.1038/nrmicro.2017.99>

5. Wang R, Braughton KR, Kretschmer D, Bach T-HL, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, DeLeo FR, Otto M. 2007. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. *Nat Med* 13:1510–1514. <https://doi.org/10.1038/nm1656>
6. Schilcher K, Horswill AR. 2020. Staphylococcal biofilm development: structure, regulation, and treatment strategies. *Microbiol Mol Biol Rev* 84:e00026-19. <https://doi.org/10.1128/MMBR.00026-19>
7. Periasamy S, Joo H-S, Duong AC, Bach T-HL, Tan VY, Chatterjee SS, Cheung GYC, Otto M. 2012. How *Staphylococcus aureus* biofilms develop their characteristic structure. *Proc Natl Acad Sci U S A* 109:1281–1286. <https://doi.org/10.1073/pnas.1115006109>
8. Schwartz Kelly, Syed AK, Stephenson RE, Rickard AH, Boles BR, Parsek MR. 2012. Functional amyloids composed of phenol soluble modulins stabilize *Staphylococcus aureus* biofilms. *PLoS Pathog* 8:e1002744. <https://doi.org/10.1371/journal.ppat.1002744>
9. Schwartz K, Ganesan M, Payne DE, Solomon MJ, Boles BR. 2016. Extracellular DNA facilitates the formation of functional amyloids in *Staphylococcus aureus* biofilms. *Mol Microbiol* 99:123–134. <https://doi.org/10.1111/mmi.13219>
10. Hanzelmann D, Joo H-S, Franz-Wachtel M, Hertlein T, Stevanovic S, Macek B, Wolz C, Götz F, Otto M, Kretschmer D, Peschel A. 2016. Toll-like receptor 2 activation depends on lipopeptide shedding by bacterial surfactants. *Nat Commun* 7: 12304. <https://doi.org/10.1038/ncomms12304>
11. Dobson CM. 2003. Protein folding and misfolding. *Nature* 426:884–890. <https://doi.org/10.1038/nature02261>
12. Sprunger ML, Jackrel ME. 2021. Prion-like proteins in phase separation and their link to disease. *Biomolecules* 11: 1014. <https://doi.org/10.3390/biom11071014>
13. Shorter J, Lindquist S. 2005. Prions as adaptive conduits of memory and inheritance. *Nat Rev Genet* 6:435–450. <https://doi.org/10.1038/nrg1616>
14. Jarosz DF, Khurana V. 2017. Specification of physiologic and disease states by distinct proteins and protein conformations. *Cell* 171:1001–1014. <https://doi.org/10.1016/j.cell.2017.10.047>
15. Saupe SJ, Jarosz DF, True HL. 2016. Amyloid prions in fungi. *Microbiol Spectr* 4. <https://doi.org/10.1128/microbiolspec.FUNK-0029-2016>
16. Newby GA, Lindquist S. 2013. Blessings in disguise: biological benefits of prion-like mechanisms. *Trends Cell Biol* 23:251–259. <https://doi.org/10.1016/j.tcb.2013.01.007>
17. Gates SN, Yokom AL, Lin J, Jackrel ME, Rizo AN, Kendsersky NM, Buell CE, Sweeny EA, Mack KL, Chuang E, Torrente MP, Su M, Shorter J, Southworth DR. 2017. Ratchet-like polypeptide translocation mechanism of the AAA+ disaggregase Hsp104. *Science* 357:273–279. <https://doi.org/10.1126/science.aan1052>
18. DeSantis ME, Leung EH, Sweeny EA, Jackrel ME, Cushman-Nick M, Neuhaus-Follini A, Vashist S, Sochor MA, Knight MN, Shorter J. 2012. Operational plasticity enables Hsp104 to disaggregate diverse amyloid and nonamyloid clients. *Cell* 151:778–793. <https://doi.org/10.1016/j.cell.2012.09.038>
19. Jackrel ME, Shorter J. 2017. Protein-remodeling factors as potential therapeutics for neurodegenerative disease. *Front Neurosci* 11: 99. <https://doi.org/10.3389/fnins.2017.00099>
20. Jackrel ME, Shorter J. 2015. Engineering enhanced protein disaggregases for neurodegenerative disease. *Prion* 9:90–109. <https://doi.org/10.1080/19336896.2015.1020277>
21. Jackrel ME, Shorter J. 2014. Reversing deleterious protein aggregation with re-engineered protein disaggregases. *Cell Cycle* 13:1379–1383. <https://doi.org/10.4161/cc.28709>
22. Jackrel ME, DeSantis ME, Martinez BA, Castellano LM, Stewart RM, Caldwell KA, Caldwell GA, Shorter J. 2014. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. *Cell* 156:170–182. <https://doi.org/10.1016/j.cell.2013.11.047>
23. Jackrel ME, Yee K, Tariq A, Chen AI, Shorter J. 2015. Disparate mutations confer therapeutic gain of Hsp104 function. *ACS Chem Biol* 10:2672–2679. <https://doi.org/10.1021/acscchembio.5b00765>
24. Tariq A, Lin J, Jackrel ME, Hesketh CD, Carman PJ, Mack KL, Weitzman R, Gambogi C, Hernandez Murillo OA, Sweeny EA, Gurpinar E, Yokom AL, Gates SN, Yee K, Sudesh S, Stillman J, Rizo AN, Southworth DR, Shorter J. 2019. Mining disaggregase sequence space to safely counter TDP-43, FUS, and alpha-synuclein proteotoxicity. *Cell Rep* 28:2080–2095. <https://doi.org/10.1016/j.celrep.2019.07.069>
25. Yasuda K, Clatterback-Soper SF, Jackrel ME, Shorter J, Mili S. 2017. FUS inclusions disrupt RNA localization by sequestering kinesin-1 and inhibiting microtubule detyrosination. *J Cell Biol* 216:1015–1034. <https://doi.org/10.1083/jcb.201608022>
26. Ryan JJ, Sprunger ML, Holthaus K, Shorter J, Jackrel ME. 2019. Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma. *J Biol Chem* 294:11286–11296. <https://doi.org/10.1074/jbc.RA119.009494>
27. Sanchez Y, Lindquist SL. 1990. HSP104 required for induced thermotolerance. *Science* 248:1112–1115. <https://doi.org/10.1126/science.2188365>
28. Alberti S, Gitler AD, Lindquist S. 2007. A suite of Gateway cloning vectors for high-throughput genetic analysis in *Saccharomyces cerevisiae*. *Yeast* 24:913–919. <https://doi.org/10.1002/yea.1502>
29. Gietz RD, Schiestl RH. 2007. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. *Nat Protoc* 2:31–34. <https://doi.org/10.1038/nprot.2007.13>
30. Khurana V, Lindquist S. 2010. Modelling neurodegeneration in *Saccharomyces cerevisiae*: why cook with baker's yeast? *Nat Rev Neurosci* 11:436–449. <https://doi.org/10.1038/nrn2809>
31. Johnson BS, McCaffery JM, Lindquist S, Gitler AD. 2008. A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. *Proc Natl Acad Sci U S A* 105:6439–6444. <https://doi.org/10.1073/pnas.0802082105>
32. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD, Weissman JS. 2011. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLN. *PLoS Biol* 9:e1000614. <https://doi.org/10.1371/journal.pbio.1000614>
33. Treusch S, Hamamichi S, Goodman JL, Matlack KES, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS, Han H, Lindhagen-Persson M, Reiman EM, Evans DA, Bennett DA, Olofsson A, DeJager PL, Tanzi RE, Caldwell KA, Caldwell GA, Lindquist S. 2011. Functional links between A β toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. *Science* 334:1241–1245. <https://doi.org/10.1126/science.1213210>
34. Outeiro TF, Lindquist S. 2003. Yeast cells provide insight into alpha-synuclein biology and pathobiology. *Science* 302:1772–1775. <https://doi.org/10.1126/science.1090439>
35. Kayatekin C, Amasino A, Gaglia G, Flannick J, Bonner JM, Fanning S, Narayan P, Barrasa MI, Pincus D, Landgraf D, Nelson J, Hesse WR, Costanzo M, AMP T2D-GENES Consortium, Myers CL, Boone C, Florez JC, Lindquist S. 2018. Translocon declogger ste24 protects against IAPP oligomer-induced proteotoxicity. *Cell* 173:62–73. <https://doi.org/10.1016/j.cell.2018.02.026>
36. Bolognesi B, Faure AJ, Seuma M, Schmiedel JM, Tartaglia GG, Lehner B. 2019. The mutational landscape of a prion-like domain. *Nat Commun* 10: 4162. <https://doi.org/10.1038/s41467-019-12101-z>
37. Newberry RW, Leong JT, Chow ED, Kampmann M, DeGrado WF. 2020. Deep mutational scanning reveals the structural basis for α -synuclein activity. *Nat Chem Biol* 16:653–659. <https://doi.org/10.1038/s41589-020-0480-6>
38. Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rüb U, Auburger G, Trojanowski JQ, Lee VM-Y, Van Deerlin VM, Bonini NM, Gitler AD. 2010. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature* 466:1069–1075. <https://doi.org/10.1038/nature09320>
39. Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, Bosco DA, Hayward LJ, Brown RH, Lindquist S, Ringe D, Petsko GA, Weissman JS. 2011. A yeast model of FUS/TLN-dependent cytotoxicity. *PLoS Biol* 9:e1001052. <https://doi.org/10.1371/journal.pbio.1001052>
40. Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, Schüle B, Lippard SJ, Tsai L-H, Krainc D, Buchwald SL, Jaenisch R, Lindquist S. 2013. Identification and rescue of α -synuclein toxicity in Parkinson patient-derived neurons. *Science* 342:983–987. <https://doi.org/10.1126/science.1245296>
41. Tardiff DF, Jui NT, Khurana V, Tambe MA, Thompson ML, Chung CY, Kamadurai HB, Kim HT, Lancaster AK, Caldwell KA, Caldwell GA, Rochet J-C, Buchwald SL, Lindquist S. 2013. Yeast reveal a "druggable" Rsp5/

- Nedd4 network that ameliorates α -synuclein toxicity in neurons. *Science* 342:979–983. <https://doi.org/10.1126/science.1245321>
42. Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, Pulst SM, Taylor JP, Rigo F, Gitler AD. 2017. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. *Nature* 544:367–371. <https://doi.org/10.1038/nature22038>
43. Grosz M, Kolter J, Paprotka K, Winkler A-C, Schäfer D, Chatterjee SS, Geiger T, Wolz C, Ohlsen K, Otto M, Rudel T, Sinha B, Fraunholz M. 2014. Cytoplasmic replication of *Staphylococcus aureus* upon phagosomal escape triggered by phenol-soluble modulins α . *Cell Microbiol* 16:451–465. <https://doi.org/10.1111/cmi.12233>
44. Krobitsch S, Lindquist S. 2000. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. *Proc Natl Acad Sci U S A* 97:1589–1594. <https://doi.org/10.1073/pnas.97.4.1589>
45. Alberti S, Halfmann R, Lindquist S. 2010. Biochemical, cell biological, and genetic assays to analyze amyloid and prion aggregation in yeast. *Methods Enzymol* 470:709–734. [https://doi.org/10.1016/S0076-6879\(10\)70030-6](https://doi.org/10.1016/S0076-6879(10)70030-6)
46. Tayeb-Fligelman E, Tabachnikov O, Moshe A, Goldshmidt-Tran O, Sawaya MR, Coquelle N, Colletier JP, Landau M. 2017. The cytotoxic *Staphylococcus aureus* PSMA3 reveals a cross-alpha amyloid-like fibril. *Science* 355:831–833. <https://doi.org/10.1126/science.aaf4901>
47. Salinas N, Colletier JP, Moshe A, Landau M. 2018. Extreme amyloid polymorphism in *Staphylococcus aureus* virulent PSMA peptides. *Nat Commun* 9:3512. <https://doi.org/10.1038/s41467-018-05490-0>
48. Zaman M, Andreasen M. 2020. Cross-talk between individual phenol-soluble modulins in *Staphylococcus aureus* biofilm enables rapid and efficient amyloid formation. *Elife* 9: e59776. <https://doi.org/10.7554/eLife.59776>
49. Wang X, Thompson CD, Weidenmaier C, Lee JC. 2018. Release of *Staphylococcus aureus* extracellular vesicles and their application as a vaccine platform. *Nat Commun* 9:1379. <https://doi.org/10.1038/s41467-018-03847-z>
50. Goldschmidt L, Teng PK, Riek R, Eisenberg D. 2010. Identifying the amyloids, proteins capable of forming amyloid-like fibrils. *Proc Natl Acad Sci U S A* 107:3487–3492. <https://doi.org/10.1073/pnas.0915166107>
51. Jackrel ME, Shorter J. 2014. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. *Dis Model Mech* 7:1175–1184. <https://doi.org/10.1242/dmm.016113>
52. Michalska K, Zhang K, March ZM, Hatzos-Skintges C, Pintilie G, Bigelow L, Castellano LM, Miles LJ, Jackrel ME, Chuang E, Jedrzejczak R, Shorter J, Chiu W, Joachimiak A. 2019. Structure of *Calcarisporiella thermophila* Hsp104 disaggregase that antagonizes diverse proteotoxic misfolding events. *Structure* 27:449–463. <https://doi.org/10.1016/j.str.2018.11.001>
53. Castellano LM, Bart SM, Holmes VM, Weissman D, Shorter J. 2015. Repurposing hsp104 to antagonize seminal amyloid and counter HIV infection. *Chem Biol* 22:1074–1086. <https://doi.org/10.1016/j.chembiol.2015.07.007>
54. Ryan JJ, Bao A, Bell B, Ling C, Jackrel ME. 2021. Drivers of Hsp104 potentiation revealed by scanning mutagenesis of the middle domain. *Protein Sci* 30:1667–1685. <https://doi.org/10.1002/pro.4126>
55. Jackrel ME, Tariq A, Yee K, Weitzman R, Shorter J. 2014. Isolating potentiated Hsp104 variants using yeast proteinopathy models. *J Vis Exp* 93: e52089. <https://doi.org/10.3791/52089>